At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 28 enrolled
Drug / intervention
Placebo +1 moredrug
Likely dose
Nicotinamide riboside 250 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
NIRVANA: NIcotinamide Riboside in SARS-CoV-2 pAtients for reNAl Protection
The University of Texas Health Science Center at San Antonio·interventional·Posted Mar 26, 2021·Updated Dec 26, 2023
In Brief
A Phase 2 clinical trial evaluating Placebo and Nicotinamide riboside for SARS-CoV-2 Infection and Acute Kidney Injury. Completed, enrolled 28 participants across 4 sites.
Detailed Summary
An interventional clinical trial using oral nicotinamide riboside (NR) in hospitalized patients with COVID-19 infection and acute kidney injury to determine the effect of NR on whole blood nicotinamide adenine dinucleotide (NAD+) levels and to evaluate safety of the use of NR.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSARS-CoV-2 Infection, Acute Kidney Injury
CountriesUnited States
Timeline
Phase 2CompletedFinished
20222023202420252026
First PostedMar 2021
Enrollment StartJun 2021
Primary CompletionDec 2021
Study CompletionJan 2022
TodayJul 2026
First PostedMar 26, 2021
Enrollment StartJun 11, 2021
Primary CompletionDec 9, 2021
Study CompletionJan 3, 2022
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 5.3 years ago
Interventions
Placebodrug
Placebo capsule containing inert ingredient
Nicotinamide ribosidedrug
250 mg Nicotinamide riboside capsules